^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + Cipterbin (inetetamab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.
Published date:
05/25/2023
Excerpt:
The 3-month PFS rate in 46 patients was 71.84%. The confirmed ORR was 28% (13/46), include one (2.17%) patient achieved complete response. The median PFS was 5.59 months….Final efficacy and safety results were consistent with previous ICU study preliminary analyses. The ICU study showed a favorable benefit-risk profile and is an important option for Chinese patients with HER2-positive MBC after at least two lines of HER2-directed therapies with trastuzumab and TKIs.
Secondary therapy:
UTD1
DOI:
10.1200/JCO.2023.41.16_suppl.1042
Trial ID:
Source:
Title:
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study.
Published date:
05/26/2022
Excerpt:
Inetetamab plus camrelizumab and utidelone showed promising efficacy and acceptable safety profile in patients with HER2-positive advanced breast cancer after progression on at least two lines of HER2-directed therapies with trastuzumab and TKIs.
DOI:
10.1200/JCO.2022.40.16_suppl.e13030
Trial ID:
